Literature DB >> 17466846

Deep anterior lamellar keratoplasty in post-laser in situ keratomileusis keratectasia.

Alberto Villarrubia1, Juan J Pérez-Santonja, Elisa Palacín, Paz Rodríguez-Ausín P, Antonio Hidalgo.   

Abstract

We describe a technique using deep anterior lamellar keratoplasty (DALK) in 5 eyes that developed keratectasia after LASIK. The technique is based on surgical manipulation that allows visualization of the lamellar dissection depth using a posterior approach to reach the predescemetic space. The mirror effect, indentation effect, and folding effect were used to determine proximity to Descemet's membrane. The same diameter donor and recipient buttons were used to correct myopia. The donor button without Descemet's membrane was placed using 10-0 nylon sutures. No intraoperative or postoperative complications occurred. The mean best spectacle-corrected visual acuity changed from 0.16 diopter (D) +/- 0.05 (SD) (range 0.10 to 0.25 D) before DALK to 0.68 +/- 0.19 D (range 0.5 to 1.0 D) after DALK. Deep anterior lamellar keratoplasty may be a better alternative than penetrating keratoplasty for any pathology with healthy endothelium.

Entities:  

Mesh:

Year:  2007        PMID: 17466846     DOI: 10.1016/j.jcrs.2006.12.035

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

1.  "Double bubble" deep anterior lamellar keratoplasty for management of corneal stromal pathologies.

Authors:  Vishal Jhanji; Jacqueline Beltz; Namrata Sharma; Enrique Graue; Rasik B Vajpayee
Journal:  Int Ophthalmol       Date:  2011-07-30       Impact factor: 2.031

2.  Deep anterior lamellar keratoplasty: indications, surgical techniques and complications.

Authors:  Farid Karimian; Sepehr Feizi
Journal:  Middle East Afr J Ophthalmol       Date:  2010-01

3.  Femtosecond laser-assisted anterior lamellar keratoplasty for the treatment of stromal corneal pathology.

Authors:  Yan Lu; Liping Yang; YiRui Ge; Xiangfei Chen; Zhenping Huang
Journal:  BMC Ophthalmol       Date:  2015-03-01       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.